GEORGE SIMEON CEO George Simeon, CEO of Curevo, and experienced business executive in the healthcare industry. He has worked globally with Novartis (Switzerland), J&J (Europe), SK Telecom (South Korea), GHX (Europe) and GS1 (USA & Europe). Advisor to early-stage companies on growth strategies, strategic alliances, fundraising, and market entry.
LISA SHELTON Associate Director of Clinical Operations Lisa Shelton, Associate Director of Clinical Operations and Licensed Adult Nurse Practitioner (ARNP). A successful leader in clinical trial investigation and study management in both sponsor and clinical site roles. Sponsor roles in clinical development and operations of first-in-human, phase 1 vaccine, and immunotherapy oncology studies. Experienced sub-investigator for first-in-human, and phase 1-3 trials in infectious disease vaccine and immunotherapy allergy trials.
EMMA FRITZEN Senior Program Manager Emma Fritzen is the Senior Program Manager for Curevo and has proven experience developing and managing contracts, scope, and budget in clinical operations. Emma also has experience with GMP and laboratory oversight, management of teams, and represents Clinical Operations in cross-functional initiatives.
NIKKI TURAKHIA Clinical Operations Manager Nikki is a clinical research specialist with experience in coordinating phase I, II & III oncology, and sleep disorder trials. Over the past ten years, Nikki has worked as a formulation chemist in the cosmetic industry and as a clinical research coordinator at clinical sites. Her expertise lies in the formulation, project management, and implementing efficient, high-impact, and well-organized clinical studies.
ANNA WREM Program Manager Anna Wrem is the Program Manager at Curevo. She has extensive experience in laboratory operations, cradle-to-grave management of grants and contracts from various funding sources, budget projections, and analysis within the research and development setting.
SHANNAN MORAN Office Manager Shannan has over 30 years of experience in administrative, project, and event management. She has extensive experience in the healthcare and research industries. With a background in both, for-profit and non-profit organizations.
GREGORY S. CURHAN CFO Greg Curhan has over 35 years of operational, financial, capital markets, and strategic advisory experience in various sectors including investment banking and medical device/life sciences. Mr. Curhan is currently a partner at FLG Partners, a leading CFO consulting and board advisory firm in Silicon Valley.
JULIE A. BROOKS General Counsel and Corporate Secretary Julie Brooks has over 30 years of experience as Chief Legal & Compliance Officer and Secretary for international public and private corporations in life sciences, medical devices and ecommerce. She has advised Boards and CEOs of 5 NASDAQ and 5 VC-backed companies as General Counsel as well as counseling multiple Biotechnology, Molecular Diagnostics and Medical Device Companies operating globally.
DAVID KOELLE, MD Dr. Koelle is a professor of Medicine and Allergy and Infectious Diseases at the University of Washington. His research focuses on the T cell immune response to viruses in the alphaherpesvirus family, including varicella-zoster virus (VZV), the cause of shingles, as well as herpes simplex virus (HSV). Candidate HSV vaccines have been advanced through discovery, pre-clinical, and clinical stages of development. The laboratory also performs immune monitoring tests for specimens from vaccine clinical trials. Studies are sponsored by the US National Institutes of Health and by biotechnology and pharmaceutical companies. In addition to research, Dr. Koelle sees patients and assists with T cell-based diagnostic testing at the University of Washington.
STEVEN REED, PhD Steve Reed is CEO of HDT Bio in Seattle, and Curevo’s Executive Advisor and Director. His academic appointments include Professor of Medicine at Cornell University Medical College in New York and a Research Professor of Pathobiology at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Review Board of the National Institutes of Health, and has served as a member of diagnostic and vaccine steering committees of the World Health Organization. Steve’s research interests have focused on the immunology of intracellular infections, and the development of vaccines and diagnostics for both cancer and infectious diseases. In addition to HDT, he has founded the Infectious Disease Research Institute (IDRI) and co-founded two other biotech companies, Immune Design Corp and Corixa Corp.
PETER GILBERT, PhD Peter Gilbert is a biostatistician whose research centers on design and analysis of randomized clinical trials for preventive vaccines against HIV and other pathogens, including dengue, malaria, and herpes zoster. Dr. Gilbert received his Ph.D. in biostatistics from the University of Washington in 1996. Following five years at Harvard Biostatistics, he has been at the Fred Hutchinson Cancer Research Center and the University of Washington. Dr. Gilbert’s two main research activities over the past 20 years have been leading for the Statistical Data Management Center of the HIV Vaccine Trials Network, and methodological and applied statistical research for evaluation of vaccine efficacy and evaluation of immunological/viral sequence correlates of vaccine efficacy.
Myron J. Levin is a Professor of Pediatrics & Medicine at the University of Colorado School of Medicine (UCSOM) in the section of Pediatric Infectious Diseases and Epidemiology, and he is the Associate Director of the Pediatric HIV Clinic. He graduated from Harvard Medical School in 1960 and completed a residency in Internal Medicine at the Bronx Municipal Hospital Center (Einstein Medical School). He spent three years at the National Institutes of Health; the last two years devoted to research in molecular virology. He returned to Harvard in 1969 to complete a fellowship in Infectious Diseases and, as an Associate Professor, to become the first Chief of Infectious Diseases at the Sidney Farber Cancer Center (now the Dana-Farber Cancer Institute). In 1982, he moved to Colorado as a Professor and Chief of Pediatric Infectious Diseases. In 2002, he resigned from this role but remained as Director of the Vaccine Research clinic. His research interests are in clinical virology, antiviral therapy, vaccinology, and immune responses to vaccines. He has published more than 450 peer-reviewed papers, chapters and books.
Hannah Nam is a senior investigator and the head of infectious disease research in MOGAM Institute for Biomedical Research. She has over 10 years of research and development in industry and has experience in infectious disease area including preventative vaccines and therapeutics. Her main research focuses are on early research, preclinical efficacy, and immunogenicity studies.